carotuximab IV (ENV-105) / Tracon Pharma, Kairos Pharma 
Welcome,         Profile    Billing    Logout  

5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carotuximab IV (ENV-105) / Kairos Pharma
NCT05534646: Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer

Recruiting
2
100
US
Apalutamide, Carotuximab
Edwin Posadas, MD, Enviro Therapeutics, Inc.
Castration-resistant Prostate Cancer
01/27
01/27
NCT01757652: Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma

Recruiting
2
32
US
anti-endoglin monoclonal antibody TRC105, TRC105, pharmacological study, pharmacological studies, laboratory biomarker analysis, quality-of-life assessment, quality of life assessment
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
01/00
 
NCT02520063: Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Hourglass Jan 2017 - Dec 2017 : From P1b/2 trial in combination with Femara and TRC105 for breast cancer
Checkmark Initiation of dosing in P1b/2 trial in combination with Femara and TRC105 in breast cancer
Feb 2016 - Feb 2016: Initiation of dosing in P1b/2 trial in combination with Femara and TRC105 in breast cancer
Completed
1/2
15
US
Letrozole, Femara, Everolimus, Afinitor, TRC105
University of Alabama at Birmingham, Novartis Pharmaceuticals, Tracon Pharmaceuticals Inc.
Breast Cancer
12/22
12/22
NCT05401110: Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Recruiting
1
60
US
Osimertinib, TAGRISSO, Carotuximab, ENV105, TRC105
Karen Reckamp, MD, MS, Enviro Therapeutics, Inc.
Non Small Cell Lung Cancer, Lung Cancer
01/25
01/26
NCT02354612: Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial

No Longer Available
N/A
US
TRC105, Chimeric Antibody (TRC105) to CD105, Bevacizumab, Avastin, Axitinib, Inlyta, Pazopanib, Votrient, Capecitabine, Xeloda
Tracon Pharmaceuticals Inc.
Solid Tumors
 
 

Download Options